Galcanezumab shows similar pregnancy outcomes to placebo, highlighting the need for more real-world safety data in patients ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs for millions of people.

But experiencing random dizzy spells throughout the day is nothing short of unnerving. The potential causes can range from something as innocuous as slacking on your hydration to an ear condition or ...

Once-daily rimegepant 75 mg is effective and well-tolerated for short-term prevention of fasting-related headache in adults ...

Company News Published 06/18/2025, 07:21 AM 0 AbbVie’s atogepant shows superior results in migraine prevention trial ABBV -0.77% ...

Despite available treatments, over 50% of people currently using preventive medications still qualify for additional preventive therapy. Atogepant, marketed as AQUIPTA in the EU and QULIPTA in the U.S ...

64.1% of atogepant users saw migraine days cut by half, compared to 39.3% for topiramate. Market-moving news hits Benzinga Pro first—get a 30-minute edge and save 60% this 4th of July. Add Comment ...

AbbVie (NYSE: ABBV) today announced positive topline results from its Phase 3 TEMPLE multicenter, randomized, double-blind, head-to-head study evaluating the tolerability, safety and efficacy of ...

For episodic migraine prevention, Qulipta’s dosage is either 10 milligrams (mg), 30 mg, or 60 mg once per day. For chronic migraine prevention, the typical dosage is 60 mg once per day.

AbbVie beat out a competitor's migraine-fighting drug in terms of dose tolerability in a head-to-head study. The North Chicago-based drugmaker said its Phase 3 study of atogepant (Qulipta) in a ...

Dealing with a headache or migraine is never fun, but doctors and dietitians say these foods may offer some relief. Anna Gragert (she/her/hers) was previously the lifestyle editor at HelloGiggles ...